retatrutide clinical trial obesity 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN TRIALS, is showing incredible results, with some Eli Lilly and Company's Retatrutide

The field is evolving rapidly, but retatrutide currently holds the weight loss efficacy record among investigational compounds

In STEP 1, participants without diabetes who received 2.4mg of semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks

Ferrannini E

Nonetheless, this classical view has been challenged by the development of thiazolidinediones, which possess potent insulin-sensitizing properties despite having very low to absent PPAR-binding affinity 51

Retatrutides Phase 2 data also demonstrated robust improvements in blood pressure, fasting glucose, and triglycerides

The GLP-1 peptide found in all other mammalian species binds the human GLP-1R with an IC50 of 7.9 10 10 M (Table 2), whereas the monotreme GLP-1 peptides bind the human and platypus GLP-1R with 50 fold lower affinity